3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
11
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Stomach Neoplasms
3
Neoplasms
3
HER2-positive Breast Cancer
3
Colorectal Neoplasms
3
Advanced Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
HER2-Positive Primary Breast Cancer
1
HER2 Overexpression
1
Glioma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
vocimagene amiretrorepvec
1
trastuzumab deruxtecan
1
entinostat
1
cediranib
1
carboxyamido-triazole
1
Thalidomide
1
Temozolomide
1
Sirolimus
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Flucytosine
1
Fentanyl
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Docetaxel
1
Biological Therapy
1
90Y-octreotide, DOTA-Tyr(3)-
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
trastuzumab deruxtecan
×
Breast
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled